OncoMatch/Clinical Trials/NCT06362694
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
Is NCT06362694 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Dabrafenib + Trametinib for anaplastic thyroid cancer.
Treatment: Dabrafenib + Trametinib — This pilot phase 2 study evaluates the effectiveness and safety of the Rechallenge concept in patients with BRAF-positive anaplastic thyroid cancer after progression on anti-BRAF therapy. Patients with BRAF-positive anaplastic thyroid cancer who were previously treated with dabrafenib and trametinib (with a clinical or objective response at the start of treatment) and later with tumor progression during anti-BRAF therapy and subsequent lines of chemotherapy are scheduled to undergo targeted therapy (repeated administration of dabrafenib and trametinib in standard doses) and evaluate the outcomes according to the primary and secondary endpoints.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Tumor Agnostic
Biomarker criteria
Required: BRAF V600 mutation
presence of a mutation in the BRAF V600 gene
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: BRAF inhibitor + MEK inhibitor (dabrafenib, trametinib)
documented progression during targeted therapy with dabrafenib + trametinib
Must have received: taxane-containing chemotherapy — second or third line
documented progression during at least one line of chemotherapy (use of taxane-containing chemotherapy is mandatory)
Cannot have received: BRAF inhibitor + MEK inhibitor (dabrafenib, trametinib)
Exception: primary resistance (absence of initial clinical and radiological response to therapy with dabrafenib and trametinib (response criteria - primary objective response according to RECIST 1.1 criteria and duration of response of at least 3 months))
primary resistance (absence of initial clinical and radiological response to therapy with dabrafenib and trametinib (response criteria - primary objective response according to RECIST 1.1 criteria and duration of response of at least 3 months))
Cannot have received: taxane-containing chemotherapy
Exception: absence of taxane-containing chemotherapy as second or third line
absence of taxane-containing chemotherapy as second or third line
Lab requirements
Blood counts
adequate function of internal organs and bone marrow
Kidney function
adequate function of internal organs and bone marrow
Liver function
adequate function of internal organs and bone marrow
adequate function of internal organs and bone marrow
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06362694 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BRAF inhibitor + MEK inhibitor, taxane-containing chemotherapy disqualifies patients from enrollment.
Does this trial require BRAF?
Yes, BRAF V600 mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify